<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04626778</url>
  </required_header>
  <id_info>
    <org_study_id>CRO-2020-08-BAC-HP-CA-BGS</org_study_id>
    <nct_id>NCT04626778</nct_id>
  </id_info>
  <brief_title>Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria in Saliva and Bioaerosol Contamination</brief_title>
  <official_title>Clinical Efficacy of Single-Use of Peroxyl Mouthwash for Reducing Bacteria in Saliva and Bioaerosol Contamination Phase I</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Colgate Palmolive</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Colgate Palmolive</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the anti-bacterial, pre-procedural, clinical efficacy of Peroxyl mouthwash (1.5%&#xD;
      hydrogen peroxide) in saliva and the reduction of bioaerosol contamination as compared to a&#xD;
      matching placebo mouthwash (0.0% hydrogen peroxide)&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Qualified subjects will be enrolled and randomized to either one of the two study groups,&#xD;
      balanced on the basis of their initial gingival index scores. Saliva samples will be&#xD;
      collected from participants prior to rinsing with their assigned mouthwash (1.5% hydrogen&#xD;
      peroxide or 0.0% hydrogen peroxide) for one minute and then expectorate. Saliva samples will&#xD;
      again be collected immediately after, at 30 min, and 60 min after rinsing. All collected&#xD;
      saliva samples will be placed in sterile vials, labeled with subject information and&#xD;
      transferred to the microbiology laboratory for analysis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 8, 2020</start_date>
  <completion_date type="Actual">December 15, 2020</completion_date>
  <primary_completion_date type="Actual">December 15, 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Each subject will be randomized to receive one of the two possible study products.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
    <masking_description>A blinded randomized controlled parallel group design trial</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the Colony Forming Unit of total bacteria in saliva and in bioaerosol</measure>
    <time_frame>baseline, 30 minutes &amp; 60 minutes</time_frame>
    <description>Saliva samples will be collected from participants prior to rinsing with their assigned mouthwash (1.5% hydrogen peroxide or 0.0% hydrogen peroxide) for one minute and then expectorate. Saliva samples will again be collected immediately after, at 30 min, and 60 min after rinsing. All collected saliva samples will be placed in sterile vials, labeled with subject information and transferred to the microbiology laboratory for analysis.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Peroxyl</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>1.5% Hydrogen Peroxide mouthwash</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo mouthwash</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.0% Hydrogen peroxide mouthwash</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Peroxyl Mouthwash</intervention_name>
    <description>Mouthwash</description>
    <arm_group_label>Peroxyl</arm_group_label>
    <other_name>1.5% HP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Mouthwash</intervention_name>
    <description>Mouthwash</description>
    <arm_group_label>placebo mouthwash</arm_group_label>
    <other_name>0.0% HP Mouthwash</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Potential subjects must meet ALL of the following criteria:&#xD;
&#xD;
               -  Subjects, ages 18-70, inclusive.&#xD;
&#xD;
               -  Availability for the duration of this clinical research study.&#xD;
&#xD;
               -  Good general health.&#xD;
&#xD;
               -  At least 20 natural teeth.&#xD;
&#xD;
               -  Gingivitis Index 1.0 (LÃ¶e-Silness).&#xD;
&#xD;
               -  Signed Informed Consent Form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Potential subjects must NOT HAVE ANY of the following conditions:&#xD;
&#xD;
               -  Symptoms consistent with COVID-19 or have tested positive.&#xD;
&#xD;
               -  Presence of orthodontic bands.&#xD;
&#xD;
               -  Tumor(s) of the soft or hard tissues of the oral cavity.&#xD;
&#xD;
               -  Advanced periodontal disease (purulent exudate, tooth mobility, and/or extensive&#xD;
                  loss of periodontal attachment or alveolar bone) or peri-implantitis.&#xD;
&#xD;
               -  Five or more carious lesions requiring immediate restorative treatment.&#xD;
&#xD;
               -  Use of antibiotic one-month prior to entry into the study.&#xD;
&#xD;
               -  Participation in any other clinical study or test panel within the one month&#xD;
                  prior to entry into the study.&#xD;
&#xD;
               -  Dental prophylaxis during the past two weeks prior to baseline examinations.&#xD;
&#xD;
               -  History of allergies to oral care/personal care consumer products or their&#xD;
                  ingredients.&#xD;
&#xD;
               -  On any prescription medicines that might interfere with the study outcome.&#xD;
&#xD;
               -  An existing medical condition that prohibits not eating or drinking for periods&#xD;
                  up to 4 hours.&#xD;
&#xD;
               -  History of alcohol or drug abuse.&#xD;
&#xD;
               -  Self-reported pregnant or lactating subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yiming Li, DDS/PhD/MSD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Loma Linda University School of Dentistry, Center for Dental Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Loma Linda University School of Dentistry, Center for Dental Research</name>
      <address>
        <city>Loma Linda</city>
        <state>California</state>
        <zip>92350</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>November 5, 2020</study_first_submitted>
  <study_first_submitted_qc>November 11, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">November 13, 2020</study_first_posted>
  <last_update_submitted>January 19, 2021</last_update_submitted>
  <last_update_submitted_qc>January 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mouthwash</keyword>
  <keyword>Saliva</keyword>
  <keyword>Bioaerosol</keyword>
  <keyword>Bacteria</keyword>
  <keyword>Gingivitis</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydrogen Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>All IPD that underlie results in a publication</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>after analysis is completed</ipd_time_frame>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

